Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan for GI toxicity prophylaxis in multiple myeloma
NCT04682405Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing Uproleselan + Melphalan with Placebo + Melphalan (2 arms). Primary endpoint: Change in Diarrhea as Assessed Per CTCAE v5.0. Started May 2021; status: completed.
02
Drugs
uproleselan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04682405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682405.